Literature DB >> 2483354

Bladder outflow tract obstruction and urinary retention from benign prostatic hypertrophy treated by balloon dilatation.

K P Gill1, L S Machan, D J Allison, G Williams.   

Abstract

Forty-eight men with urodynamically proven bladder outflow tract obstruction (BOO) and 19 with retention secondary to benign prostatic hypertrophy were treated by balloon dilatation of the prostate as out-patients; 31 were dilated with 20 mm and 36 with 25 mm balloons. Of the 48 men with BOO, 37 had repeat cystometrograms at intervals ranging from 3 to 11 months after dilatation and 33 (89%) remained obstructed by urodynamic criteria. Of 6 who only had a peak flow rate assessment, 5 had a flow less than 12 ml/s. Of the 19 patients in retention only 3 were able to void and all are obstructed. Symptoms of hesitancy, poor stream, frequency and nocturia were improved in less than 50% of patients. No reliable correlation was found between objective response and balloon size, length of time of dilatation, prostate size or morphology, detrusor pressure or stability, or post-dilatation urethrogram appearances. Balloon dilatation to 25 mm is not adequate therapy for bladder outflow tract obstruction or urinary retention from prostatic hypertrophy.

Entities:  

Mesh:

Year:  1989        PMID: 2483354     DOI: 10.1111/j.1464-410x.1989.tb05321.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

Review 1.  Review of current and future approaches to the management of benign prostatic hyperplasia.

Authors:  J C Gingell
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

2.  Balloon dilatation of the prostate--should it have a place in the urologist's armamentarium?

Authors:  J A Vale; P D Miller; R S Kirby
Journal:  J R Soc Med       Date:  1993-02       Impact factor: 5.344

3.  Efficacy and safety of transurethral split of prostate for benign prostatic hyperplasia: a meta-analysis.

Authors:  Yiyu Huang; Jiaxin Li; Shan Yang; Daozhang Yuan; Shusheng Wang
Journal:  BMC Urol       Date:  2020-09-03       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.